Illumina Kits OP-101-1003 Illumina 二代测序组合试剂盒 销售代理商

Illumina 二代测序组合试剂盒 销售代理商

"Illumina/TruSight Tumor 170 Kit, For Use with NextSeq (24 Samples)/OP-101-1003/1 Ea

" OP-101-1003 Illumina 产品编号： OP-101-1003美  元  价： $0.00会  员  价： 待定品       Pai： Illumina产       地： 美国公       司： Illumina, Inc.产品分类： 其它>其它试剂>芯片公司分类： Clinical Research Products "Product Highlights:

TruSight Tumor 170, a next-generation sequencing assay designed to cover 170 genes associated with common solid tumors, is an enrichment-based targeted panel that simultaneously analyzes DNA and RNA, covering a wide range of genes and variant types. The comprehensive nature provides laboratories with a deep view into the genetics of cancer.

Comprehensive Coverage of Cancer-Related Variants

Assessment of fusions, splice variants, insertions/deletions and single-nucleotide variants (SNVs), and amplifications in one assay using DNA and RNA creates efficiencies in sample usage, time, and cost.

Accurate Results from Low-Quality Samples1

Variant detection with as little as 40 ng DNA and RNA input, and as low as 5% mutant allele frequency, maximizes the results from precious formalin-fixed paraffin-embedded (FFPE) samples.

Integrated, Streamlined Workflow

DNA and RNA are prepared in parallel with an integrated workflow following DNA shearing/CDNA synthesis.

Specifications:

Assay Time ~2 days (Library Prep)

Hands-On Time ~10.5 hours

Input Quantity 40 ng DNA and/or RNA

Method Targeted RNA Sequencing,Targeted DNA Sequencing

Variant Class Single Nucleotide Polymorphisms (SNPs),Gene Fusions,Somatic Variants,Structural Variants,Insertions-Deletions (indels),Copy Number Variants (CNVs)

Specialized Sample Types FFPE,Low Input

System Compatibility NextSeq 550,NextSeq 500,HiSeq 2500

Technology Sequencing

Species Category Human

Cancer Type Solid Tumor

Scientific Posters:

AACR 2017: TruSight Tumor 170 and Tumor Mutational Burden

Results of analysis indicate that TruSight Tumor 170, with comprehensive coverage of cancer-related genes, shows high concordance with whole exome sequencing for accurate assessment of tumor mutational burden.

Learn More

AACR 2017: TruSight Tumor 170 and Solid Tumor Profiling Analytical Performance with FFPE Samples

Standard extractions from FFPE embedded samples provide sufficient material (40ng) in >95% of samples that were extracted by Illumina. This data shows that the TruSight Tumor 170 panel is a robust assay that generates passing sample QC data in >85% of samples with varying quality, and in >95% of samples that have quality metrics that fall within the recommendations for the kit.

Learn More

AACR 2017: TruSight Tumor 170 for Small Nucleotide Variations and Gene Amplifications in FFPE DNA Samples

TruSight Tumor 170 can achieve high sensitivity and specificity for the detection of somatic variants (small variants and CNVs) from DNA extracted from FFPE tissues.

Learn More

AACR 2017: TruSight Tumor 170 for Fusions and Splice Variants in FFPE RNA Tumor Samples

Through examining limit of detection in the context of RNA expression, this study shows that TruSight Tumor 170 provides high sensitivity and specificity in RNA variant calling down to 5 copies of transcript per ng of input.

Learn More"

Illumina公司，致力于新一代测序和芯片技术的生产与开发，提供产品与应用资讯

Illumina公司创立于1998年4月，是遗传变异和生物学功能分析领域的的产品、技术和服务供应商。通过帮助客户加快实现生物信息的采集、分析和应用，来改善人类健康。

Sequencing Kits/ Microarray Kits/Informatics Products/ Clinical Research Products/In Vitro Diagnostic/ Products/Molecular Biology Reagents/ Accessory Products

上海易汇生物科技有限公司于17年正式代理Illumina公司基因芯片、二代测序NGS测序仪及相关测序试剂盒等产品

咨询illumina MiSeq测序试剂盒等产品欢迎您致电 上海易汇生物科技有限公司：1850 1609 238张经理

Illumina 二代测序组合试剂盒 销售代理商